The crucial role of IL-4 in AD pathogenesis is further supported by the clinical efficacy of dupilumab, an IL-4/IL-13-targeting biologic, which has been shown to significantly improve disease outcomes in both IgE-allergic and non-IgE-allergic AD phenotypes [31]. Here, IL13 is linked to Alzheimer disease.